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Abstract
Glutamate racemase (MurI) catalyzes the interconversion of L-glutamate to
D-glutamate, one of the essential amino acids present in the peptidoglycan. In
addition to this essential enzymatic function, MurI from Escherichia coli, Bacillus
subtilis and Mycobacterium tuberculosis inhibit DNA gyrase activity. A single gene
for murI found in the Mycobacterium smegmatis genome was cloned and over-
expressed in a homologous expression system to obtain a highly soluble enzyme.
In addition to the racemization activity, M. smegmatis MurI inhibits DNA gyrase
activity by preventing DNA binding of gyrase. The sequestration of the gyrase by
MurI results in inhibition of all reactions catalyzed by DNA gyrase. More
importantly, MurI overexpression in vivo in mycobacterial cells provides protec-
tion against the action of ciprofloxacin. The DNA gyrase-inhibitory property thus
appears to be a typical characteristic of MurI and would have probably evolved to
either modulate the function of the essential housekeeping enzyme or to provide
protection to gyrase against gyrase inhibitors, which cause double-strand breaks in
the genome.
Introduction
All bacteria obtain their structural integrity from the pepti-
doglycan layer, a large polymeric structure that is located
between the cytoplasmic and the outer membranes of the
cell wall. Peptidoglycan is formed from linear chains of two
alternating amino sugars, namely N-acetylglucosamine and
N-acetylmuramic acid, to which a small group of amino
acids (stem peptide) consisting of L-alanine, D-alanine,
D-glutamate and either lysine or diaminopimelic acid are
covalently attached (Meroueh et al., 2006). Glutamate race-
mase (MurI) catalyzes the interconversion of L-glutamate
to D-glutamate, one of the integral components present in
peptidoglycan. It is ubiquitously inherited in bacteria
although with undetectable activity, except in some lactoba-
cilli (Gallo & Knowles, 1993).
By virtue of being unique to bacteria, peptidoglycan and
the enzymes involved in its biosynthesis have been consid-
ered to be attractive targets for the design and development
of new antibacterial agents. Approaches in this direction
include rational, structure-based drug design to inhibit the
synthesis of the stem peptide portion of the peptidoglycan
precursor (Tanner et al., 1996; Zeng et al., 1998; Reck et al.,
2001). MurI, a provider for D-glutamate, has been shown to
be important in bacteria including pathogenic species
(Hoskins et al., 1999; Glavas & Tanner, 2001). Being an
essential enzyme, it is already used as a target for antibacter-
ial drug discovery. The first discovered, moderately potent
MurI inhibitors competitively interfered with the L/D trans-
formation (Tanner & Miao, 1994; Glavas & Tanner, 1997; de
Dios et al., 2002). The design of D-glutamate-based analo-
gues and their structure activity relationship studies led to
the discovery of several potential MurI inhibitors (Glavas &
Tanner, 1997; de Dios et al., 2002).
Besides the racemization function, few glutamate race-
mases have been shown to possess an additional property of
gyrase inhibition. Escherichia coli MurI was the first one to
be shown to inhibit E. coli gyrase, but only in the presence of
the peptidoglycan precursor (Ashiuchi et al., 2002). Subse-
quently, one of the two glutamate racemases from Bacillus
subtilis, the YrpC isozyme, was shown to influence the
activity of DNA gyrase in a precursor independent fashion
(Ashiuchi et al., 2003). MurI from Mycobacterium tubercu-
losis inhibits DNA gyrase by preventing the DNA-binding
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activity of the enzyme (Sengupta et al., 2006). Gyrase
inhibition seems to be an additional attribute of some of
the glutamate racemases, but not all, as Glr isozyme from
B. subtilis has no effect on gyrase activity (Ashiuchi et al.,
2003).
MurI from M. tuberculosis cloned in E. coli was found to
be in the insoluble inclusion bodies (Sengupta et al., 2006).
Attempts to express the protein in soluble form in E. coli
were unsuccessful. The active enzyme was recovered after
urea refolding and was then used for biochemical character-
ization. It is important to obtain the protein in soluble form
and in large quantities to carry out structural studies and
detailed characterization.
Like M. tuberculosis, the Mycobacterium smegmatis gen-
ome contains a single gene for glutamate racemase although
the genome of the latter is larger. Understanding the
characteristics of M. smegmatis MurI is important because
M. smegmatis is often used as a surrogate for M. tuberculosis
for a variety of studies. Comparison of the properties of
MurI from both the species would form the basis for its use
for in vivo screening of antimycobacterial compounds.
In the present study, M. smegmatis MurI has been
expressed and purified in soluble form with high specific
activity. The studies reveal that MurI from M. smegmatis is
also a bifunctional enzyme. It inhibits DNA gyrase in
addition to its racemization activity. Further, overexpression
of the enzyme in M. smegmatis provides protection to the
organism against fluoroquinolones.
Materials and methods
Bacterial strains and plasmids
Escherichia coli strains DH5a and M. smegmatis mc2155
strains were used for cloning and overexpression of
M. smegmatis MurI, respectively. Genomic DNA from
M. smegmatis mc2155 was isolated as described (Madhusu-
dan et al., 1994). The murI gene was cloned in the pJAM2
vector (Triccas et al., 1998). pBR322 and pUC18 plasmids
were used for the biochemical assays.
Enzyme and substrate preparation
Escherichia coli DNA gyrase subunits, GyrA and GyrB, were
purified as described (Maxwell & Howells, 1999). Mycobac-
terium smegmatis DNA gyrase was purified by the method
standardized before (Manjunatha et al., 2002). Supercoiled
pUC18 and pBR322 were prepared by standard protocols
(Sambrook et al., 1989).
Cloning of murI
The murI gene was PCR amplified using M. smegmatis mc2
genomic DNA as a template and primers Pf (50-TCTGAC
CATATGAGCGATCGACT-30) and Pr (50-GGTTTCGCGA
CACAGATCATCTTC-30) containing NdeI and NruI sites,
respectively. The gene was amplified with Pfu DNA poly-
merase. In brief, 50 ng of genomic DNA was processed in a
50 mL reaction volume containing PCR buffer [20mM Tris-
HCl pH 8.8, 10mM KCl, 10mM (NH4)2SO4, 2mMMgSO4,
0.1% Triton X-100, 0.1mgmL1 bovine serum albumin
(BSA)], 250 mM deoxynucleoside triphosphates, 20 pmol of
each primer and 1U of Pfu polymerase (Promega). Ampli-
fications were carried out in a GeneAmp PCR system 9700
of Applied Biosystems. The first cycle, consisting of a 5-min
denaturation at 94 1C, was followed by 30 cycles each of
1min at 94 1C, 45 s at 56 1C, and 2min, 30 s, at 68 1C, with a
final extension for 5min at 68 1C.
The amplicon was subjected to NdeI digestion, followed
by end filling with Klenow polymerase, and ligated to an
ScaI digested pJAM2 vector to generate a pJAM2-msmurI
construct.
Expression and purification of MurI
The M. smegmatis mc2155 cells harboring the pJAM2-
msmurI construct were grown in Middle brook 7H9 media.
The cells were harvested, resuspended in sonication buffer
containing 50mM Tris-HCl pH-8.0, 1mM potassium
glutamate, 0.1mM phenyl methane sulfonyl fluoride,
0.5mM MgCl2, and sonicated. Lysis was followed by
ultracentrifugation at 100 000 g at 4 1C for 3 h. The super-
natant was subjected to 60% ammonium sulfate fractiona-
tion. The pellet containing MurI was dialyzed against buffer
A (50mM Tris-HCl pH-8.0, 0.2% 2-mercaptoethanol,
0.1mM phenyl methane sulfonyl fluoride, 10% glycerol)
and loaded onto a MonoQ column, washed with buffer A
containing 200mM NaCl and the enzyme was eluted with a
gradient of 200–500mM NaCl. The peak fractions contain-
ing MurI were pooled and dialyzed against the same buffer,
reloaded onto MonoQ column and eluted with a shallow
gradient of 250–350mM NaCl. The fractions containing
MurI were pooled and subjected to 0–60% ammonium
sulfate fractionation. The pellet was dissolved in 2mL of
the buffer A, dialyzed and loaded onto a Sephacryl S100 gel
filtration column. The eluted fractions containing MurI
were pooled, dialyzed, concentrated and stored at  70 1C.
Racemization activity
The racemization activity was assessed by a coupled assay as
described previously (Sengupta et al., 2006). MurI was
incubated in the presence of D-glutamate for 30min at
37 1C and then rapidly heated to inactivate the enzyme and
further assayed for L-glutamate using NAD1/L-glutamate
dehydrogenase. The increase in A340 nm was monitored for
10min at 25 1C using a Beckman DU640 UV/vis
spectrophotometer.
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DNA supercoiling and relaxation reactions
Supercoiling assays were carried out at 37 1C with 300 ng
of relaxed pUC18 and 10 nM DNA gyrase from either
M. smegmatis in supercoiling buffer [Buffer S: 35mM Tris-
HCl pH 7.5, 5mM MgCl2, 25mM potassium glutamate,
2mM spermidine, 2mM ATP, 50mg L1 BSA and 90mg L1
yeast tRNA in 5% (v/v) glycerol]. Relaxation assays were
carried out with 150 nM of gyrase using supercoiled pBR322
in buffer S devoid of ATP, either in the presence or in the
absence of MurI for 60min at 37 1C and terminated with
0.6% sodium dodecylsulfate (SDS). The assay mixtures were
resolved on 1% agarose gel in 40mM Tris-actetate buffer
containing 1mM EDTA.
Electrophoretic mobility shift assay (EMSA)
Assays were carried out using an end-labeled 240-bp DNA
fragment encompassing the strong gyrase site (SGS) from
pBR322. One nanomolar of labeled DNA was incubated
with 100 nM of DNA gyrase either in the absence or in the
presence of different concentrations of MurI in buffer S for
30min at 4 1C, followed by electrophoresis on 4% native
polyacrylamide gel as described (Sengupta et al., 2006). The
free DNA and bound complexes were quantitated using a
phosphorimager.
Cleavage reactions
DNA cleavage assays were carried out in buffer S with a
supercoiled pBR322 substrate or radiolabeled 240-bp SGS
for 30min at 30 1C, and the gyrase–DNA complex was
trapped by adding 0.2% SDS, followed by proteinase K
(90mgmL1) digestion for 30min. In case of drug-induced
cleavage reactions, ciprofloxacin (30mgmL1) was included
in the assay. The reaction mixtures were resolved on 1%
agarose gel or 8% urea–polyacrylamide gel electrophoresis
(PAGE). The substrate and cleaved DNA products were
quantitated using a phosphorimager.
ATPase assay
The DNA-stimulated ATPase activity of DNA gyrase was
monitored in buffer S containing 2mM ATP, 10 mgmL1
DNA (240 bp from pBR322) and 0.02 mCi of [g-32P] ATP
(3000Cimmol1). In order to assess the intrinsic ATPase
activity, 1 mM GyrB was used while DNA and GyrA were
omitted. The assays were carried out as described earlier
(Sengupta et al., 2006). The aqueous layer (1.0mL) was
resolved on polyethyleneimine-cellulose by thin-layer chro-
matography using 1.2M LiCl, and 0.1mM EDTA as the
chase buffer. The spots corresponding to ATP and Pi were
quantitated using a phosphorimager.
Growth profiles and cytotoxicity assays
Mycobacterium smegmatis mc2155 cells containing either the
pJAM2 vector or the pJAM2-msmurI construct were grown
inMiddlebrook 7H9media supplemented with 0.4% glucose
at 37 1C, and growth was monitored by measuring A600nm
after every 3 h. The effect of MurI on the toxicity caused by
drugs (ciprofloxacin and mitomycin C) was tested by spot-
ting various concentrations of the drug on a lawn of
M. smegmatis mc2155 containing either the pJAM2 vector
or pJAM2-msmurI constructs. The cultures were grown to
the mid-logarithmic phase and then 1% inoculums were
poured onto Middlebrook 7H9-soft agar plates (0.8% agar)
containing appropriate antibiotics. The plates were preincu-
bated for drying before the spotting. Equal volumes (2mL) of
drugs from the stock solutions of varying concentrations
were spotted on the lawn of cells, and the diameters of the
zones of inhibition were measured and tabulated to compare
the potency of the drugs for theM. smegmatis transformants.
Results
Purification of M. smegmatis MurI
The recombinant glutamate racemase was overexpressed
from the pJAM2-msmurI construct in the M. smegmatis
mc2155 strain. Constitutive high-level expression was ob-
tained without requiring acetamide-mediated induction
(Fig. 1). The identity of the protein was confirmed by the
standard tryptic mass fingerprinting technique (not shown).
The recombinant protein was found totally in the soluble
fraction in contrast to the M. tuberculosis enzyme expressed
Fig. 1. Characterization of Mycobacterium smegmatis MurI. Expres-
sion profile of M. smegmatis MurI, lane 1 and lane 2: M. smegmatis
mc2155 cell extract harboring vector pJAM2 vector uninduced and
induced with 2% acetamide, respectively, lane 3 and lane 4:
M. smegmatis mc2155 cell extract harboring pJAM2-msmurI construct
uninduced and induced with 2% acetamide, respectively, lane 5: purified
MurI.  , uninduced;1, induced with acetamide
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in E. coli. It was purified to apparent homogeneity and
racemase activity was assayed by the glutamate dehydrogen-
ase coupled assay. The specific activity was determined to be
3Umg1 of the enzyme, 1U being defined as the amount of
enzyme required to convert 1 mmol of substrate into
productmin1. The soluble protein was found to be 10-fold
more active when compared with urea-refolded M. tubercu-
losis MurI.
Mycobacterium smegmatis MurI inhibits DNA
gyrase activity
Alignment of the M. smegmatis MurI sequence with that of
the M. tuberculosis enzyme revealed that they share 82%
identity at the amino acids level. To test the effect of
M. smegmatis MurI on supercoiling activity, mycobacterial
DNA gyrase was preincubated with MurI before the addi-
tion of relaxed pUC18. MurI inhibited supercoiling activity
of DNA gyrase in a dose-dependent fashion (Fig. 2a). To test
the effect of MurI on DNA gyrase-mediated relaxation, DNA
gyrase was preincubated with MurI prior to the addition of a
supercoiled pBR322 DNA substrate. MurI was found to
inhibit the DNA relaxation activity of gyrase as well
(Fig. 2b). MurI inhibited the decatenation activity and also
the activity of gyrase from a heterologous source i.e. from
E. coli at comparable levels (not shown). Hence, MurI
inhibits DNA gyrase across the species barrier unlike the
toxins CcdB and microcin B17 (Chatterji et al., 2001), which
are specific inhibitors of E. coli DNA gyrase.
MurI inhibits at the step of DNA binding
To assess the effect of MurI on gyrase–DNA complex
formation, EMSAs were performed by preincubating DNA
gyrase with different concentrations of MurI, prior to the
addition of DNA. MurI inhibited the formation of the
gyrase–DNA noncovalent complex in a dose-dependent
manner (Fig. 3a). If DNA binding by gyrase is the target of
MurI action, the DNA-stimulated ATPase activity of the
enzyme should be affected while its intrinsic activity should
be unaltered. Reactions were carried out in the presence of a
linear DNA substrate as described in ‘Materials and meth-
ods’. MurI inhibited the DNA-stimulated ATPase activity of
DNA gyrase (Fig. 3b). However, as expected, the intrinsic
ATPase activity of DNA gyrase was not altered in the
presence of MurI (Fig. 3c).
To test the effect of MurI at the cleavage step, DNA gyrase
was preincubated with MurI and the cleavage assays were
performed both with the supercoiled plasmid DNA and the
radiolabeled linear DNA substrates. Ciprofloxacin is known
to arrest DNA gyrase at the cleavage step and calcium
(Ca21) ions inhibit the religation and stimulate the DNA
cleavage activity of the enzyme (Gmunder et al., 1995; Lewis
et al., 1996; Maxwell, 1999). SDS and proteinase K treatment
removes the covalently attached protein and a cleaved DNA
Fig. 2. Inhibition of DNA gyrase activities by
Mycobacterium smegmatis MurI. (a) Effect
on supercoiling activity of M. smegmatis
DNA gyrase. Ten nanomolars of DNA gyrase
was used for the supercoiling reaction; lane 1:
relaxed pUC18 alone, lane 2: gyrase activity in
the presence of 400 nM BSA, lanes 3–5: gyrase
reaction in the presence of increasing
concentrations of MurI (50, 100, 200, 400 nM);
(b) relaxation activity of DNA gyrase. One
hundred and fifty nanomolars of enzyme was
used. Lane 1: supercoiled pUC18 alone, lane 2:
DNA gyrase activity in the presence of BSA; lane
3: gyrase reaction in the presence of 400 nM
MurI. All the assays were repeated at least three
times. The representative figures have been
presented.
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fragment can be visualized on the gel. Unlike ciprofloxacin
and calcium ions, MurI did not stimulate DNA gyrase-
mediated cleavage (Fig. 3d, compare lanes 3 with lanes 4 and
5). MurI also abrogated ciprofloxacin-induced cleavage on a
linear DNA substrate (Fig. 3e). From all these observations,
it is concluded that M. smegmatis MurI also inhibits the
DNA-binding activity of DNA gyrase in a manner similar to
that of M. tuberculosis MurI. Because, DNA binding is the
first step in the catalytic cycle of gyrase, all the subsequent
steps are affected in the presence of MurI. Moreover,
ciprofloxacin targets the gyrase–DNA covalent complex for
stabilization, and MurI interaction with DNA gyrase
prevents ciprofloxacin action in vitro.
MurI protects the bacteria from the action of
ciprofloxacin
Because MurI appears to protect against ciprofloxacin
action in vitro (Fig. 3d and e), to evaluate the scenario
in vivo, the cytotoxic action of quinolones was tested by
Fig. 3. Effect of MurI on different steps of the gyrase reaction cycle. (a) Effect of MurI on noncovalent complex formation; EMSAs were carried out
with 100 nM DNA gyrase and 1 nM radiolabeled 240-bp SGS at 4 1C; lane1: free SGS, lane 2: DNA gyrase in the presence of 400 nM BSA, lanes 3 and 4:
gyrase in the presence of 200 and 400nM of MurI, respectively. (b) DNA stimulated ATPase activity. Reactions were performed with 40 nM
Mycobacterium smegmatis DNA gyrase and 10 mgmL1 DNA (240-bp SGS from pBR322), lane 1: gyrase alone, lane 2: gyrase in the presence of 400 nM
BSA, lanes 3 and 4: gyrase in the presence of 200 and 400 nM of MurI, respectively, lane 5: gyrase in the presence of 1 mgmL1 novobiocin, (c) intrinsic
ATPase activity. Reactions were performed with 1 mM Escherichia coli GyrB, lane 1: GyrB alone, lane 2: GyrB in the presence of 400 nM BSA, lanes 3 and
4: GyrB in the presence of 200 and 400 nM of MurI respectively, lane 5: GyrB in the presence of 1 mgmL1 novobiocin, (d) cleavage reactions with
supercoiled pBR322 substrate, 50 nM DNA gyrase used; lane 1: supercoiled substrate alone, lane 2: DNA gyrase alone, lane 3: gyrase reaction in the
presence of 0.4mM MurI, lane 4: gyrase reaction in the presence of calcium ions, lane 5: gyrase reaction in the presence of ciprofloxacin (30 mgmL1);
Mg21 ions omitted and 5mM Ca21 ions added in lane 4 (e) cleavage with linear radiolabeled DNA (SGS). 100 nM DNA gyrase used; lane 1: 240-bp SGS
alone, lane 2: cleavage by DNA gyrase, lanes 3–8: gyrase mediated cleavage in the presence of increasing concentrations of MurI (100, 200, 300, 400,
500, 600 nM). Ciprofloxacin (30 mgmL1) added in all the lanes. A representative set of data is presented based on several sets of experiments.
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spotting different concentrations of ciprofloxacin on a lawn
ofM. smegmatis cells overexpressing MurI. The formation of
a zone of inhibition and its size is indicative of the sensitivity
of the cells to ciprofloxacin. The diameters of the zone of
inhibition were measured (Table 1). The reduced diameters
of zone of inhibition with ciprofloxacin in case of MurI
overexpressing cells indicate that MurI overexpression leads
to increased resistance against ciprofloxacin. MurI-mediated
protection was specific towards DNA damage caused by
trapped gyrase–DNA covalent complexes as MurI did not
provide protection against mitomycin C, a general DNA-
damaging agent (Table 1). These in vivo experiments sup-
port the in vitro data that MurI prevents the DNA-binding
activity of gyrase and by doing so, protects gyrase against the
cytotoxic action of gyrase poison, ciprofloxacin. The growth
profile of M. smegmatis overexpressing MurI was compared
with the cells harboring only the pJAM2 vector. There were
no significant differences in growth upon MurI expression
and plasmid topology remained unaltered (not shown).
From these results, it appears that MurI-mediated inhibition
of DNA gyrase could be transient and gyrase is able to
overcome it probably by means of relaxation-stimulated
transcription (RST) (Unniraman & Nagaraja, 1999).
Discussion
Mycobacterium smegmatis glutamate racemase exhibits a
dual role by possessing racemase activity and DNA gyrase
inhibition. Thus, in this respect it is similar to the glutamate
racemases from E. coli, M. tuberculosis and YrpC from
B. subtilis (Ashiuchi et al., 2002, 2003; Sengupta et al.,
2006). However, unlike the E. coli enzyme, theM. smegmatis
MurI enzyme appears to be active independent of any
peptidoglycan precursor as far as racemization as well as
gyrase inhibitory properties are concerned. The first report
on inhibition of DNA gyrase by glutamate racemase
(Ashiuchi et al., 2002) was rather surprising as the enzyme
appeared to have no role in DNA transaction processes and
seemed to be dedicated only to cell wall component bio-
synthesis. Subsequent studies from the same group with the
enzyme from B. subtilis (Ashiuchi et al., 2003), the authors’
studies withM. tuberculosisMurI (Sengupta et al., 2006) and
the present work with the M. smegmatis enzyme indicate
that inhibition of DNA gyrase activity is a typical character-
istic of at least one group of glutamate racemases. The
interaction and inhibitory effect of MurI seems to be specific
to gyrase and conserved across the species barrier. Because,
MurI from distantly related organisms exhibit this bifunc-
tional behavior, the bifunctionality does not seem to be a
mere coincidence and may have some functional signifi-
cance. It is suggested that the gyrase-inhibitory properties of
glutamate racemases might have evolved in eubacteria to
serve some important physiological purpose.
DNA gyrase is a vital and indispensable enzyme in
bacteria functioning in several DNA transaction processes.
Among a large repertoire of the gyrase inhibitors, coumarins
and quinolones have been studied extensively with respect
to their mechanism of action (Lewis et al., 1996; Maxwell,
1999). Now, a newer group of inhibitors is emerging with
the discovery of the chromosomally encoded inhibitors such
as GyrI (Nakanishi et al., 1998; Chatterji & Nagaraja, 2001),
MfpA (Montero et al., 2001; Hegde et al., 2005), Qnr
(Martinez-Martinez et al., 2003; Tran et al., 2005; Arsene &
Leclercq, 2007) and MurI (Ashiuchi et al., 2002, 2003;
Sengupta et al., 2006). In spite of having no sequence or
structural similarities, all these endogenous inhibitors share
a common feature, as their mode of inhibition is to prevent
binding of gyrase to DNA. Thus, none of these proteins are
cytotoxic, as they do not arrest the enzymatic step of DNA
gyrase. Cytotoxicity usually arises due to induction and
accumulation of double-strand breaks in the genome fol-
lowing the trapping of gyrase in the form of enzyme–DNA
covalent complexes, which form roadblocks to the cellular
DNA transaction machineries.
In the present study, soluble mycobacterial MurI is
purified by overexpressing it in M. smegmatis itself.
Although it inhibits DNA gyrase activity in vitro, MurI
protects M. smegmatis against the action of ciprofloxacin in
vivo. These studies indicate that MurI may be a survival
strategy used by the cell to safeguard the essential house-
keeping enzyme, DNA gyrase from the gyrase-targeting
poisons. Alternatively, MurI could bind transiently to DNA
gyrase to sequester it away from DNA in situations wherein
excessive supercoiling has to be modulated. Another plau-
sible explanation is that MurI-mediated sequestration of
gyrase serves as a ‘check point’ during the process of cell
Table 1. Diameters of zone of inhibition for different dilutions of
ciprofloxacin and mitomycin C on a lawn of Mycobacterium smegmatis
strain harboring either the vector pJAM2 or pJAM2-msmurI
pJAM2 vector (mm) pJAM2-msmurI (mm)
Ciprofloxacin (mg)
0.5 15 0.6 10 0.5
0.4 13 0.5 9 0.6
0.3 10 0.6 5 0.5
0.1 8 0.5 3 0.6
Mitomycin C (mg)
20 12 0.8 12 0.5
10 9 0.7 9 0.4
5 7 0.6 8 0.1
2.5 5 0.7 5 0.6
1.25 4 0.5 4 0.2
Mycobacterium smegmatis cultures were grown in Middlebrook 7H9
broth till mid-logarithmic phase at 37 1C and then poured onto soft agar
plates to form the lawn. Different dilutions of the drugs were spotted
and then the plates were incubated for 3–4 days to get defined zones of
inhibition.
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division. In this model, the cell division and DNA replica-
tion would be coordinated by modulation of gyrase. An
alarming increase in the emergence of multi-drug-resistant
strains of M. tuberculosis and continuing high worldwide
incidence of tuberculosis has motivated an increasingly
active search for novel drug targets. Inhibition of the
bacterial cell wall peptidoglycan biosynthesis pathway seems
to be one of the attractive targets. MurI is already being
considered as a target for designing new antibacterial drugs
as it provides D-glutamate, a key building block for pepti-
doglycan in bacteria. Because MurI protects gyrase from the
cytotoxic effect of quinolone drugs, blocking MurI activity
along with antigyrase agents might be a more effective cell-
killing strategy, providing a synergistic effect. The produc-
tion and purification of mycobacterial MurI in large
amounts in soluble form is a step forward to the design of
high-throughput screening assays for testing potential MurI
inhibitors with the aim of developing new antimycobacterial
compounds.
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